VIRAX BIOLABS GROUP LTD (VRAX)
KYG9495L1251 - Common Stock
Overall VRAX gets a fundamental rating of 4 out of 10. We evaluated VRAX against 113 industry peers in the Health Care Providers & Services industry. VRAX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VRAX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
VRAX had negative earnings in the past year.
In the past year VRAX has reported a negative cash flow from operations.
VRAX had negative earnings in each of the past 5 years.
In the past 5 years VRAX always reported negative operating cash flow.
1.2 Ratios
VRAX has a Return On Assets of -122.79%. This is amonst the worse of the industry: VRAX underperforms 93.81% of its industry peers.
VRAX's Return On Equity of -125.47% is on the low side compared to the rest of the industry. VRAX is outperformed by 78.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -122.79% | ||
| ROE | -125.47% | ||
| ROIC | N/A |
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 32.34%, VRAX is doing good in the industry, outperforming 61.06% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for VRAX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRAX has more shares outstanding
VRAX has a worse debt/assets ratio than last year.
2.2 Solvency
VRAX has an Altman-Z score of 39.06. This indicates that VRAX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of VRAX (39.06) is better than 100.00% of its industry peers.
VRAX has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
VRAX has a Debt to Equity ratio of 0.03. This is in the better half of the industry: VRAX outperforms 78.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 39.06 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
VRAX has a Current Ratio of 25.94. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 25.94, VRAX belongs to the best of the industry, outperforming 99.11% of the companies in the same industry.
A Quick Ratio of 25.58 indicates that VRAX has no problem at all paying its short term obligations.
VRAX has a Quick ratio of 25.58. This is amongst the best in the industry. VRAX outperforms 99.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 25.94 | ||
| Quick Ratio | 25.58 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.63% over the past year.
Looking at the last year, VRAX shows a very strong growth in Revenue. The Revenue has grown by 1727.34%.
The Revenue has been growing by 9.24% on average over the past years. This is quite good.
EPS 1Y (TTM)34.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.08%
Revenue 1Y (TTM)1727.34%
Revenue growth 3Y9.24%
Revenue growth 5YN/A
Sales Q2Q%2754.29%
3.2 Future
Based on estimates for the next years, VRAX will show a very strong growth in Earnings Per Share. The EPS will grow by 48.68% on average per year.
The Revenue is expected to grow by 210.44% on average over the next years. This is a very strong growth
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VRAX's earnings are expected to grow with 48.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.68%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VRAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIRAX BIOLABS GROUP LTD
NASDAQ:VRAX (11/22/2024, 8:12:06 PM)
After market: 2 -0.01 (-0.5%)2.01
+0.07 (+3.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.18M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -122.79% | ||
| ROE | -125.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.34% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 25.94 | ||
| Quick Ratio | 25.58 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)34.63%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y68.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1727.34%
Revenue growth 3Y9.24%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y